On January 22, 2021, Dr. Kelvin Neu, a member of the Board of Directors of Prelude Therapeutics Incorporated (the Company), delivered to the Company a written resignation from the Board and all committees of the Board on which he was a member, effective January 25, 2021. Dr. Neu's decision was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. Effective on January 25, 2021, the Board appointed Julian C. Baker to fill the vacancy on the Board as a Class II Director. Mr. Baker shall hold office for a term expiring at the 2022 Annual Meeting of the Company's stockholders, which is the next stockholder meeting at which Class II directors will be elected. Mr. Baker will also serve on the Company's compensation committee and act as chairman of the Company's nominating and governance committee.